Skip to main content
. 2017 Sep 4;92(1):469–485. doi: 10.1007/s00204-017-2048-0

Fig. 6.

Fig. 6

Effect of PPARA agonist fenobrinate on zoledronate-associated nephrotoxicity. a Representative images of H&E and ORO staining of kidney sections from control mice, zoledronate-treated mice and zoledronate-treated mice with fenofibrate (Zole + fenofibrate). (scale bar 1 mm). b Masson’s trichrome staining (scale bar: 50 μm) and fibrosis markers of Fn1, collagen I and α-SMA IHC (scale bar 20 μm) from kidney sections in control, zoledronate- and zoledronate + fenofibrate-treated mice. c Western blot analysis of kidney fibrosis markers in three groups of mice above. d Relative mRNA levels of genes related to kidney fibrosis from the samples above. e Relative transcript levels of FAO-related genes in the mice above. # P < 0.05, ## P < 0.01, compared between zoledronate-treated or zoledronate + fenofibrate co-treated mice